Company profile
Inmune Bio, Inc.
NASDAQ:INMBBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEGIPANERMIN | phase2_3 | — | 1 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03943264 | phase1 | completed | 2019-11-20 | 2021-06-30 | Inmune Bio, Inc. | A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's |
| NCT05933070 | phase1 | terminated | 2020-06-15 | 2024-03-28 | Inmune Bio, Inc. | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML |
| NCT05318976 | phase2 | completed | 2022-02-28 | 2025-05-12 | Inmune Bio, Inc. | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation |
| NCT05522387 | phase2 | terminated | 2023-02-21 | 2024-06-05 | Inmune Bio, Inc. | An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease |
| NCT04370236 | phase2_3 | terminated | 2020-10-21 | 2021-10-13 | Inmune Bio, Inc. | INB03 for the Treatment of Pulmonary Complications From COVID-19 |
FDA applications (0)
No records yet.